Viatris Inc. (VTRS) Gross Margin: 34.40%
Is Viatris Inc.’s gross margin high or low?
Viatris Inc.'s gross margin of 34.40% is in line with its 5-year average of 36.31%, around the middle of its 5-year range (31.17%–41.74%).
As of Sunday, June 21, 2026. 6.02% below its 12-month average of 36.61%.
VTRS Gross Margin Chart
VTRS Average Gross Margin Chart
VTRS Current vs Average Gross Margin Chart
VTRS Gross Margin Metrics
GROSS MARGIN
34.40%
GROSS MARGIN AVG TTM
36.61%
GROSS MARGIN AVG 3Y
38.73%
GROSS MARGIN AVG 5Y
36.31%
GROSS MARGIN AVG 10Y
36.93%
GROSS MARGIN AVG 15Y
39.31%
GROSS MARGIN AVG 20Y
40.01%
CURRENT VS TTM AVG
-6.02%
CURRENT VS 3Y AVG
-11.17%
CURRENT VS 5Y AVG
-5.26%
CURRENT VS 10Y AVG
-6.85%
CURRENT VS 15Y AVG
-12.50%
CURRENT VS 20Y AVG
-14.01%
VTRS Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viatris Inc. (VTRS) | $17.90B | 34.40% | 36.61% | 38.73% | 36.31% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $17.02B | 70.03% | 66.54% | 68.95% | 69.55% |
| Hologic, Inc. (HOLX)vs › | $16.97B | 52.82% | 58.14% | 57.33% | 59.28% |
| Incyte Corporation (INCY)vs › | $19.62B | 92.48% | 92.70% | 93.10% | 93.74% |
| Labcorp Holdings Inc. (LH)vs › | $20.98B | 27.79% | 27.30% | 28.39% | 31.16% |
| DaVita Inc. (DVA)vs › | $13.34B | 31.10% | 29.95% | 30.17% | 30.48% |
| Medpace Holdings, Inc. (MEDP)vs › | $13.14B | 29.07% | 30.59% | 29.65% | 29.57% |
| Solventum Corporation (SOLV)vs › | $13.06B | 53.67% | 54.56% | 56.03% | 57.27% |
| Align Technology, Inc. (ALGN)vs › | $13.04B | 67.68% | 69.16% | 69.73% | 70.75% |
| United Therapeutics Corporation (UTHR)vs › | $22.78B | 86.58% | 88.58% | 89.63% | 90.66% |
Gross Margin Analysis
Gross Margin
34.4%
(Revenue - COGS) / Revenue
Viatris Inc. Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Viatris Inc. Gross Margin FAQ
- What is the gross margin for Viatris Inc. (VTRS)?
- The gross margin for VTRS stock is 34.40%.
- Is Viatris Inc.'s gross margin high or low?
- Viatris Inc.'s gross margin of 34.40% is in line with its 5-year average of 36.31%, around the middle of its 5-year range (31.17%–41.74%).
- What is the TTM average gross margin for Viatris Inc. (VTRS)?
- The TTM average gross margin for VTRS stock is 36.61%.
- What is the 3Y average gross margin for Viatris Inc. (VTRS)?
- The 3Y average gross margin for VTRS stock is 38.73%.
- What is the 5Y average gross margin for Viatris Inc. (VTRS)?
- The 5Y average gross margin for VTRS stock is 36.31%.
- What is the 10Y average gross margin for Viatris Inc. (VTRS)?
- The 10Y average gross margin for VTRS stock is 36.93%.
- What is the 15Y average gross margin for Viatris Inc. (VTRS)?
- The 15Y average gross margin for VTRS stock is 39.31%.
- What is the 20Y average gross margin for Viatris Inc. (VTRS)?
- The 20Y average gross margin for VTRS stock is 40.01%.
Viatris Inc. Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2025-12-31 | 35.06% |
| 2024-12-31 | 38.15% |
| 2023-12-31 | 41.74% |
| 2022-12-31 | 39.95% |
| 2021-12-31 | 31.17% |
| 2020-12-31 | 31.78% |
| 2019-12-31 | 33.89% |
| 2018-12-30 | 35.00% |
| 2017-12-30 | 40.17% |
| 2016-12-30 | 42.40% |
| 2015-12-30 | 44.71% |
| 2014-12-30 | 45.70% |
| 2013-12-30 | 44.00% |
| 2012-12-31 | 42.79% |
| 2011-12-31 | 41.82% |
| 2010-12-31 | 40.68% |
| 2009-12-31 | 40.73% |
| 2008-12-31 | 40.30% |
| 2007-12-31 | 40.14% |
| 2006-03-31 | 49.92% |
| 2005-03-31 | 49.75% |
| 2004-03-31 | 55.47% |
Related Metrics
About Viatris Inc.
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Scott Andrew Smith